1. Home
  2. Live Updates
  3. Ntagi

Live Breaking News & Updates on Ntagi

Stay informed with the latest breaking news from Ntagi on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ntagi and stay connected to the pulse of your community

NTAGI holds meeting on Covovax inclusion as heterologous booster on CoWin portal

National Technical Advisory Group on Immunisation conducted a meeting on February 8 regarding the inclusion of Covid-19 vaccine Covovax as a heterologous booster dose for adults on the CoWin portal to boost uptake of the doses, sources said on Thursday.

India , Bharat , Union-health-ministry , Serum-institute-of-india-covid , European-medicines-agency , World-health-organization , National-technical-advisory-group-on-immunisation , Serum-institute-of-india , National-technical-advisory-group , Serum-institute , Drugs-controller-general

NTAGI to discuss inclusion of Covovax in CoWIN portal as heterologous booster dose soon

The National Technical Advisory Group on Immunisation (NTAGI) is likely to meet soon to discuss inclusion of Covid vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults to boost uptake of booster doses, said official sources.

India , Bharat , Union-health-ministry , Serum-institute-of-india-covid , European-medicines-agency , World-health-organization , Serum-institute-of-india , National-technical-advisory-group-on-immunisation , National-technical-advisory-group , Serum-institute , Controller-general

'There is no surge in new covid cases'

We are well prepared in terms of surveillance, clinical services, and keeping a close eye on the international variant scenario, says NTAGI chief

Covid , Ntagi , Covid-19 , Nk-arora ,

SII Cervical cancer vaccine CERVAVAC likely to be launched in April next year

Serum Institute's vaccine is likely to be available at a much lower rate.

India , New-delhi , Delhi , Prakash-kumar-singh , Adarc-poonawalla , National-immunisation-programme , Regulatory-affairs , Serum-institute , Serum-institute-of-india , National-technical-advisory-group-on-immunisation , Department-of-biotechnology , Human-papillomavirus-vaccine

Efforts now to develop Zika virus vaccine in India: NTAGI chief Dr NK Arora

A 5-year-old girl in Karnataka tested positive for the Zika virus and has been advised to take precautionary measures.

Karnataka , India , Zika-virus , Ntagi , Dr-nk-arora , Zika-virus-vaccine , Zika-virus-symptoms , Zika-virus-outbreak , Ntagi-chief-dr-nk-arora ,

COVID-19 is much around us so take booster dose, says NTAGI's Dr NK Arora

COVID-19 is much around us so take booster dose, says NTAGI's Dr NK Arora

India , Hubspot , Ntagi , Dr-nk-arora , Cpvid-19 ,

Covid shaping up like common cold, but be cautious: NTAGI chief

mRNA & intranasal covid vaccines have the potential for precaution dose as and when appropriate data is available, says Dr N.K. Arora, Chairman, NTAGI

Dr-nk-arora , Ntagi , Covid-19 , Gennova-pharma , Mrna-vaccine , Bharat-biotech , Nasal-vaccine ,

Gap Between 2nd Covid Jab, Booster Reduced On Immunisation Group Advice: Centre

Based on the recommendations made by the National Technical Advisory Group on Immunisation (NTAGI), the interval between the second and the precaution dose of Covid vaccines was revised from nine months to six months for all beneficiaries.

Har-ghar-dastak , Lok-sabha , Amrit-mahotsava , Parliament-on , Booster-reduced-on-immunisation-group-advice , Health-bharati-pravin-pawar , National-technical-advisory-group-on-immunisation , Centre-as-on , Gap-between , Covid-jab , National-technical-advisory-group , Ghar-dastak

NTAGI may allow mixing Corbevax as booster shot with Coivishield, Covaxin

The government advisory panel is also expected to review the trial data of the country's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute of India.

India , National-technical-advisory-group-on-immunisation , Serum-institute-of-india , Drugs-controller-general , National-technical-advisory-group , Serum-institute , Standing-technical-sub-committee , Ntagi , Orbevax , Ovxin , Ovishield

Corbevax being considered as booster dose for Covishield, Covaxin jabbed people

NTAGI is considering using Corbevax as a booster vaccination against Covid-19.


India , National-technical-advisory-group-on-immunisation , Serum-institute-of-india , Allowing-corbevax , Drugs-controller-general , National-technical-advisory-group , Serum-institute , Standing-technical-sub-committee , Ntagi , Orbevax , Ovaxin